Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 11/20 | 0.65 |
| ▸ | RET | P07949 | 5/20 | 0.58 |
| ▸ | KDR | P35968 | 5/20 | 0.56 |
| ▸ | CLK1 | P49759 | 1/20 | 0.53 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.53 |
| ▸ | KIF5B | P33176 | 2/20 | 0.53 |
| ▸ | LCK | P06239 | 1/20 | 0.53 |
| ▸ | KDM1A | O60341 | 1/20 | 0.51 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6031335 | 0.92 | EGFR (0.58) | EGFRRETKDRCLK1ABCG2 | |
| SCHEMBL4374475 | 0.89 | EGFR (0.59) | EGFRRETKDRCLK1ABCG2 | |
| SCHEMBL4378175 | 0.87 | KDR (0.59) | EGFRRETKDRCLK1ABCG2 | |
| SCHEMBL6099438 | 0.87 | EGFR (0.50) | EGFRRETKDRCLK1ABCG2 | |
| SCHEMBL4375005 | 0.84 | ERBB2 (0.63) | EGFRRETKDRCLK1ABCG2 | |
| SCHEMBL4378628 | 0.84 | KDR (0.70) | EGFRRETKDR | |
| SCHEMBL4373829 | 0.84 | EGFR (0.67) | EGFRRETKDRABCG2KIF5B | |
| SCHEMBL4374222 | 0.84 | KDR (0.70) | EGFRRETKDR | |
| SCHEMBL4379803 | 0.83 | MAPK1 (0.55) | EGFRRETKDRCLK1ABCG2 | |
| Hydrochloric Acid SCHEMBL4373692 | 0.83 | EGFR (0.66) | EGFRRETKDRABCG2KIF5B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8492560-B2 | Quinazoline derivatives as angiogenesis inhibitors | ASTRAZENECA AB (SE) | 2013-07-23 | — | — | US | disclosed |
| US-20120197027-A1 | Quinazoline Derivatives as Angiogenesis Inhibitors | STOKES ELAINE S E (GB) | 2012-08-02 | — | — | US | disclosed |
| US-7074800-B1 | Quinazoline derivatives as angiogenesis inhibitors | ASTRAZENECA AB (SE) | 2006-07-11 | — | — | US | disclosed |
| EP-1553097-A1 | QUINAZOLINE DERIVATIVES AS ANGIOGENESIS INHIBITORS AND INTERMEDIATES THEREFORE | AstraZeneca AB (SE) | 2005-07-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120197027-A1 | Quinazoline Derivatives as Angiogenesis Inhibitors | VEGFA, FLT1, KDR | EGFR 500/4885RET 637/4885KDR 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.